Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.
Jian Wu,Jiawei Shen,Ying Han,Qinghua Qiao,Wei Dai,Bangshun He,Bangshun He,Rongrong Pang,Rongrong Pang,Jun Zhao,Tao Luo,Yanju Guo,Yang Yang,Qiuyue Wu,Weijun Jiang,Jing Zhang,Mingchao Zhang,Mingchao Zhang,Na Li,Na Li,Weiwei Li,Xinyi Xia +21 more
Reads0
Chats0
TLDR
In this paper, the role of interleukin-6 (IL-6) levels during SARS-CoV-2 infection was investigated and two specific treatments, namely, tocilizumab and convalescent plasma therapy (CPT), decreased the level of IL-6 and relieved inflammation.Abstract:
A comprehensive understanding of the dynamic changes in interleukin-6 (IL-6) levels is essential for monitoring and treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). By analyzing the correlations between IL-6 levels and health conditions, underlying diseases, several key laboratory detection indices, and the prognosis of 1,473 patients with the coronavirus disease 2019 (COVID-19), the role of IL-6 during SARS-CoV-2 infection was demonstrated. Our results indicated that IL-6 levels were closely related to age, sex, body temperature, oxygen saturation (SpO2) of blood, and underlying diseases. As a stable indicator, the changes in IL-6 levels could indicate the inflammatory conditions during a viral infection. Two specific treatments, namely, tocilizumab and convalescent plasma therapy (CPT), decreased the level of IL-6 and relieved inflammation. CPT has an important role in the therapy for patients with critical COVID-19. We also found that patients with IL-6 levels, which were 30-fold higher than the normal level, had a poor prognosis compared to patients with lower levels of IL-6.read more
Citations
More filters
Journal ArticleDOI
A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19
Essa M. Saied,Yousra A. El-Maradny,Alaa A. Osman,Amira M. G. Darwish,Hebatallah H. Abo Nahas,Gniewko Niedbała,Magdalena Piekutowska,Mohamed A. Abdel-Rahman,Bassem A. Balbool,Ahmed M. Abdel-Azeem +9 more
TL;DR: In 2019, the world suffered from the emergence of COVID-19 infection, one of the most difficult pandemics in recent history, and millions of confirmed deaths from this pandemic have been reported worldwide as mentioned in this paper.
Journal ArticleDOI
Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality.
Arturo Casadevall,Quigly Dragotakes,Patrick W. Johnson,Jonathon W. Senefeld,Stephen A. Klassen,R. Scott Wright,Michael J. Joyner,Nigel Paneth,Rickey E. Carter +8 more
TL;DR: In this article, a strong inverse correlation between CCP use and mortality per admission in the USA provides population-level evidence consistent with the notion that CCP reduces mortality in COVID-19 and suggests that the recent decline in usage could have resulted in excess deaths.
Posted ContentDOI
Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Convalescent Plasma Hesitancy cost lives?
Arturo Casadevall,Quigly Dragotakes,Patrick W. Johnson,Jonathon W. Senefeld,Stephen S Klassen,R. Scott Wright,Michael J. Joyner,Nigel Paneth,Rickey E. Carter +8 more
TL;DR: In this paper, the authors tracked the number of CCP units dispensed to hospitals by blood banking organizations and correlated that usage with hospital admission and mortality data over the course of the year, finding a strong inverse correlation (Pearson's correlation coefficient of -0.5176 with P = 0.00242) between CCP usage/hospital admission and deaths occurring two weeks after admission.
Journal ArticleDOI
Laboratory parameters predicting mortality of adult in-patients with COVID-19 associated cytokine release syndrome treated with high-dose tocilizumab.
Botond Lakatos,Balint Gergely Szabo,Ilona Bobek,László Gopcsa,Gabriella Beko,Noemi Kiss-Dala,Borisz Petrik,Zsofia Gaspar,Balazs Ferenc Farkas,János Sinkó,Péter Reményi,János Szlávik,István Vályi-Nagy +12 more
TL;DR: In this article, the authors evaluated high-dose (8 mg/kg) intravenous tocilizumab administration in severe and critically ill COVID-19 adult patients fulfilling predefined strict CRS criteria.
Journal ArticleDOI
Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19.
TL;DR: In this article, the authors provide an update on the efficacy and safety of the repurposed, and natural drugs to treat COVID-19 as well as the vaccines used for its prophylaxis.
References
More filters
Journal ArticleDOI
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
TL;DR: The epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of patients with laboratory-confirmed 2019-nCoV infection in Wuhan, China, were reported.
Journal ArticleDOI
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta,Daniel F. McAuley,Michael Brown,Emilie Sanchez,Rachel Tattersall,Rachel Tattersall,Jessica J Manson +6 more
TL;DR: Re-analysis of data from a phase 3 randomised controlled trial of IL-1 blockade (anakinra) in sepsis, showed significant survival benefit in patients with hyperinflammation, without increased adverse events.
Journal ArticleDOI
Detection of SARS-CoV-2 in Different Types of Clinical Specimens.
TL;DR: Results of PCR and viral RNA testing for SARS-CoV-2 in bronchoalveolar fluid, sputum, feces, blood, and urine specimens from patients with COVID-19 infection in China are described to identify possible means of non-respiratory transmission.
Journal ArticleDOI
COVID-19 and the cardiovascular system.
TL;DR: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through ACE2 receptors, leading to coronav virus disease (COVID-19)-related pneumonia, while also causing acute myocardial injury and chronic damage to the cardiovascular system.
Journal ArticleDOI
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
TL;DR: It is suggested that patients with cardiac diseases, hypertension, or diabetes, who are treated with ACE2increasing drugs, are at higher risk for severe COVID-19 infection and, therefore, should be monitored for ACE2-modulating medications, such as ACE inhibitors or ARBs.